Merck Gets FDA Approval to Expand Use of Its Top-Selling Drug, Keytruda

1. Merck's Keytruda approved for head and neck cancer treatment expansion. 2. Keytruda reduces cancer recurrence risk by 30% against standard treatments. 3. Keytruda achieved over $7 billion in Q1 sales, crucial for MRK's revenue. 4. FDA's approval could impact treatment practices significantly, shifting standard care. 5. Approximately 72,680 new head and neck cancer cases are expected by 2025.